Abstract
The Ca2+ channel blockers represent a successful group of therapeutic agents directed against cardiovascular targets, including hypertension and angina. These drugs, including the first-generation verapamil, nifedipine and diltiazem are directed against a subclass of voltage-gated Ca2+ channel - the L-type channel. Other subclasses of Ca2+ channel exist and are targets for new indications. The mechanisms of actions of the L-type blockers are discussed and the origins of their cardiovascular selectivity discussed. Although new drugs of this class directed against hypertension could be developed, there are both clinical and economic reasons that argue against such development. However, there are other possible targets to investigate where antagonists and activators of the L-type channel may be useful: such targets include fertility, neuronal growth, bone formation and epilepsy. Limitations to these approaches are discussed.
Keywords: Ca2+ channels, Ca2+ channel blockers, hypertension, angina, arrhythmias, neuronal Ca2+ channels, verapamil, diltiazem, nifedipine, 1, 4-dihydropyridines
Current Pharmaceutical Design
Title: L-Type Calcium Channels
Volume: 12 Issue: 4
Author(s): David J. Triggle
Affiliation:
Keywords: Ca2+ channels, Ca2+ channel blockers, hypertension, angina, arrhythmias, neuronal Ca2+ channels, verapamil, diltiazem, nifedipine, 1, 4-dihydropyridines
Abstract: The Ca2+ channel blockers represent a successful group of therapeutic agents directed against cardiovascular targets, including hypertension and angina. These drugs, including the first-generation verapamil, nifedipine and diltiazem are directed against a subclass of voltage-gated Ca2+ channel - the L-type channel. Other subclasses of Ca2+ channel exist and are targets for new indications. The mechanisms of actions of the L-type blockers are discussed and the origins of their cardiovascular selectivity discussed. Although new drugs of this class directed against hypertension could be developed, there are both clinical and economic reasons that argue against such development. However, there are other possible targets to investigate where antagonists and activators of the L-type channel may be useful: such targets include fertility, neuronal growth, bone formation and epilepsy. Limitations to these approaches are discussed.
Export Options
About this article
Cite this article as:
Triggle J. David, L-Type Calcium Channels, Current Pharmaceutical Design 2006; 12 (4) . https://dx.doi.org/10.2174/138161206775474503
DOI https://dx.doi.org/10.2174/138161206775474503 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Computational Studies of Molecular Targets Regarding the Adverse Effects of Isoniazid Drug for Tuberculosis
Current Pharmacogenomics and Personalized Medicine Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets The Therapeutic Role of Lamotrigine and Topiramate in A Depressive Patient with Anxiety Symptoms and Cognitive Decline: Neurometabolic Correlates
Current Clinical Pharmacology Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Lexical Characterisation of Bio-Ontologies by the Inspection of Regularities in Labels
Current Bioinformatics Ameliorative Potential of Glycyrrhiza glabra Extracts on Memory Impairments in Stress Triggered Rats
Current Traditional Medicine Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Current Drug Targets Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Decreased Plasma Level of Lipoprotein Lipase Predicted Verbal Disfluency in Chinese Type 2 Diabetes Mellitus Patients with Early Cognitive Deficits
Current Alzheimer Research